Literature DB >> 11238734

Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma.

R Abounader1, S Ranganathan, B Y Kim, C Nichols, J Laterra.   

Abstract

Scatter factor/hepatocyte growth factor (SF/HGF) and its tyrosine kinase receptor c-met are developmentally expressed, neuroprotective, and tumorigenic within the CNS. In the present study SF/HGF is shown to induce the expression of c-met in two human glioblastoma cell lines, U-373 MG and T98G, and the signaling pathways involved in this induction are dissected. SF/HGF activated mitogen-activated protein kinase (MAPK) and inhibition of either Ras or MAPK-kinase completely inhibited SF/HGF-mediated c-met induction. Inhibition of phospholipase-C (PLC) did not affect c-met induction in either cell line. Inhibition of phosphoinositide 3-kinase (PI3-kinase) substantially reduced c-met induction by SF/HGF in T98G cells but had no effect in U-373 MG cells. Protein kinase C (PKC) inhibition reduced c-met induction in T98G cells but not in U-373 MG cells. SF/HGF induced the expression of c-fos and c-jun mRNA and increased the levels of AP-1 transcription factor in both cells lines as determined by AP-1-luciferase reporter expression. Transfection of either cell line with TAM-67, a dominant negative for the jun transactivation domain, completely inhibited AP-1 and c-met induction by SF/HGF. These results support a model of c-met induction by SF/HGF in human glioma cells that uniformly involves Ras, MAPK, and AP-1 and additionally involves PI3-kinase and PKC in some cell lines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238734     DOI: 10.1046/j.1471-4159.2001.00158.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  22 in total

1.  Transcriptional gene expression profiles of HGF/SF-met signaling pathway in colorectal carcinoma.

Authors:  Xue-Nong Li; Yan-Qing Ding; Guo-Bing Liu
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

2.  Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma.

Authors:  Gregory A Watson; Xinglu Zhang; Michael T Stang; Ryan M Levy; Pierre E Queiroz de Oliveira; William E Gooding; James G Christensen; Steven J Hughes
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

Review 3.  Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.

Authors:  William Tomaszewski; Luis Sanchez-Perez; Thomas F Gajewski; John H Sampson
Journal:  Clin Cancer Res       Date:  2019-02-25       Impact factor: 12.531

4.  Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation.

Authors:  Heike Peterziel; Julia Müller; Andreas Danner; Sebastian Barbus; Hai-Kun Liu; Bernhard Radlwimmer; Torsten Pietsch; Peter Lichter; Günther Schütz; Jochen Hess; Peter Angel
Journal:  Neuro Oncol       Date:  2012-03-06       Impact factor: 12.300

5.  PTEN inhibits adrenomedullin expression and function in brain tumor cells.

Authors:  Simone A Betchen; Sergei Musatov; Jill Roberts; John Pena; Michael G Kaplitt
Journal:  J Neurooncol       Date:  2006-07-05       Impact factor: 4.130

6.  Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.

Authors:  Ying Zhang; Kaitlyn E Farenholtz; Yanzhi Yang; Fadila Guessous; Charles G Dipierro; Valerie S Calvert; Jianghong Deng; David Schiff; Wenjun Xin; Jae K Lee; Benjamin Purow; James Christensen; Emanuel Petricoin; Roger Abounader
Journal:  Clin Cancer Res       Date:  2013-02-05       Impact factor: 12.531

7.  An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Authors:  Fadila Guessous; Ying Zhang; Charles diPierro; Lukasz Marcinkiewicz; Jann Sarkaria; David Schiff; Sean Buchanan; Roger Abounader
Journal:  Anticancer Agents Med Chem       Date:  2010-01       Impact factor: 2.505

8.  Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.

Authors:  Jeannine Garnett; Vaibhav Chumbalkar; Brian Vaillant; Anupama E Gururaj; Kristen S Hill; Khatri Latha; Jun Yao; Waldemar Priebe; Howard Colman; Lisa A Elferink; Oliver Bogler
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

Review 9.  Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.

Authors:  V Finisguerra; H Prenen; M Mazzone
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

10.  PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.

Authors:  Hal E Crosswell; Anindya Dasgupta; Carlos S Alvarado; Tanya Watt; James G Christensen; Pradip De; Donald L Durden; Harry W Findley
Journal:  BMC Cancer       Date:  2009-11-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.